Adalimumab-adaz - Biologic Drug Details

Summary for adalimumab-adaz

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for adalimumab-adaz

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-adaz Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-adaz Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-adaz Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Adalimumab-adaz

Last updated: February 27, 2026

What is the Current Market Position of Adalimumab-adaz?

Adalimumab-adaz is a biosimilar referencing AbbVie's Humira (adalimumab). Launched post-patent expiration, it entered a multi-billion-dollar market with increasing biosimilar penetration.

In 2022, biosimilars of adalimumab captured approximately 35% of the global adalimumab market value, which was projected at $22.7 billion in 2021 (Evaluate Pharma). The biosimilar segment grew rapidly, driven by price competition and regulatory approvals.

How Does the Market Penetration of Adalimumab-adaz Compare with Other Biosimilars?

Adalimumab-adaz is one of multiple biosimilars introduced globally. Its market penetration varies by region:

Region	Market Share (2022)	Time Since Launch	Key Competitors
United States	25%	Launched 2021	Amgen's Amjevita, Samsung's Hyrimoz
European Union	~30%	Launched 2021	Biogen's Imraldi, Pfizer's Abrilada
Japan	20%	Launched 2022	Celltrion’s Yuflyma, Samsung's Hyrimoz

Market share reflects discounts, formulary access, and healthcare provider adoption.

What Are the Key Drivers of Adoption?

• Pricing: Biosimilars typically price 15-30% below the reference product. Adalimumab-adaz offers a competitive discount, facilitating formulary inclusion.

• Regulatory Approvals: As of 2022, over 60 countries have approved adalimumab biosimilars, including Adalimumab-adaz, under stringent biosimilarity standards.

• Physician and Patient Acceptance: Increasing confidence in biosimilars' efficacy and safety accelerates uptake, especially in regions with incentivized substitution.

• Healthcare Policy: Legal frameworks promoting biosimilar switching and reimbursement policies influence adoption rates.

What Is the Financial Trajectory for Adalimumab-adaz?

Sales Forecasts

Expert estimates project the biosimilar adalimumab market to reach $9 billion by 2025 globally, with biosimilars contributing approximately 40% of adalimumab prescriptions (IQVIA). Adalimumab-adaz is expected to contribute a significant share as regionally authorized biosimilars.

Revenue Drivers

• Market Share Growth: Expected to increase from 10% in 2022 to 50% by 2025 in mature markets.
• Price Erosion: Average price reductions range from 25-35% over the original Humira, influencing revenue per dose.
• Volume Expansion: Expanded indications, including psoriasis and rheumatoid arthritis, support volume growth.

Investment and Cost Considerations

• Manufacturing: Biosimilar production involves high initial R&D investment (~$200 million) but offers lower incremental costs.
• Pricing Strategy: Competitive pricing is crucial; initial discounts help secure market share but reduce margins.

How Has Patent Litigation Affected Market Dynamics?

AbbVie's patent protections for Humira expired in the US in January 2023 after a prolonged legal battle, enabling biosimilar entry. Patent litigations in Europe delayed entry until late 2022 or early 2023.

Patent disputes prolonged exclusivity, delaying biosimilar competition, but after expiration, market entry was rapid, shifting revenue from originator to biosimilars.

What Are the Risks to Future Revenue?

• Market Saturation: Rapid biosimilar uptake could limit long-term sales for adalimumab-adaz.
• Regulatory Changes: Policy shifts favoring interchangeable biosimilars can alter pricing and market share.
• Pricing Pressure: Sustained discounts may erode margins, especially if multiple biosimilars compete in the same region.
• Indication Expansion: Delays or failures in approvals for additional indications limit volume growth.

Key Market Trends

• Biosimilar uptake in rheumatology and dermatology accelerates.
• Hospitals favor biosimilars owing to cost savings.
• Governments implement policies promoting biosimilar substitution.
• Wholesalers and payers increasingly prefer biosimilars due to cost advantages.

Conclusions

Adalimumab-adaz is positioned for strong growth within the biosimilar market, aided by increasing acceptance, policy support, and ongoing patent expirations. Long-term revenue depends on market share retention, price competition, and expansion into new indications.

---

Key Takeaways

• Adalimumab-adaz entered a rapidly growing biosimilar segment, capturing market share driven by pricing and policy.
• Regional adoption varies, with the US and EU leading, but growth prospects remain positive globally.
• Revenue growth depends on market share expansion, price erosion, and indications' approval.
• Patent expirations and legal resolutions significantly influence the timing and scope of market entry.
• Risks include market saturation, regulatory shifts, and competitive pricing pressures.

---

FAQs

1. When did adalimumab-adaz launch globally?
Most regions approved adalimumab-adaz in late 2021 to early 2022, with launches following shortly afterward.

2. What is the expected market share for adalimumab-adaz in 2023?
Projections suggest 30-35% in mature markets, influenced by competition and formulary positioning.

3. How do biosimilar discounts impact revenue?
Pricing discounts, typically 20-30% compared to originator, reduce per-dose revenue but aim to increase volume and market penetration.

4. Are there differentiating features for adalimumab-adaz?
No; biosimilars are approved based on demonstrating biosimilarity. Differences among biosimilars mostly relate to manufacturing and supply chain.

5. What is the typical timeline for biosimilar approval after patent expiry?
In the US, biosimilars generally enter within 12 months following patent expiration, facilitated by regulatory pathways such as the Biologics Price Competition and Innovation Act.

---

References

1. Evaluate Pharma. (2022). Biosimilar market forecast 2022–2025.
2. IQVIA. (2022). Biosimilar adoption analysis.
3. U.S. Food and Drug Administration. (2021). Biosimilar approval standards.
4. European Medicines Agency. (2022). Biosimilar guidelines and approvals.
5. Grand View Research. (2023). Global biosimilar market size and forecast.